Impact of early rasburicase on incidence of clinical tumor lysis syndrome in lymphoma

References

• Darmon M, Vincent F, Camous L, et al. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br J Haematol. 2013;162:489–497.
   PubMed Web of Science ®Google Scholar
• Montesinos P, Lorenzo I, Martín G, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 2008;93:67–74.
   PubMed Web of Science ®Google Scholar
• Canet E, Cheminant M, Zafrani L, et al. Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome? Leuk Lymphoma. 2014;55:2362–2367.
   PubMed Web of Science ®Google Scholar
• Aygencel G, Turkoglu M, Turkoz Sucak G, et al. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2014;29:618–626.
   PubMed Web of Science ®Google Scholar
• Darmon M, Guichard I, Vincent F, et al. Prognostic significance of acute renal injury in acute tumor lysis syndrome. Leuk Lymphoma. 2010;51:221–227.
   PubMed Web of Science ®Google Scholar
• Durani U, Shah ND, Go RS. In‐hospital outcomes of tumor lysis syndrome: a population‐based study using the national inpatient sample. Oncologist 2017;22:1506–1509.
   PubMed Web of Science ®Google Scholar
• Garimella PS, Balakrishnan P, Ammakkanavar NR, et al. Impact of dialysis requirement on outcomes in tumor lysis syndrome. Nephrology 2017;22:85–88.
   PubMed Web of Science ®Google Scholar
• Ahsan Ejaz A, Pourafshar N, Mohandas R, et al. Uric acid and the prediction models of tumor lysis syndrome in AML. PLoS One 2015;10:5–15.
   Web of Science ®Google Scholar
• Koratala A, Singhania G, Alquadan KF, et al. Serum uric acid exhibits inverse relationship with estimated glomerular filtration rate. Nephron 2016;134:231–237.
   PubMed Web of Science ®Google Scholar
• Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149:578–586.
   PubMed Web of Science ®Google Scholar
• Chawla LS, Bellomo R, Bihorac A, et al. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol. 2017;13:241–257.
   PubMed Web of Science ®Google Scholar
• Vadhan-raj S, Fayad LE, Fanale MA, et al. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012;23:1640–1645.
   PubMed Web of Science ®Google Scholar
• Vines AN, Shanholtz CB, Thompson JL. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients. Ann Pharmacother. 2010;44:1529–1537.
   PubMed Web of Science ®Google Scholar
• Yu X, Liu L, Nie X, et al. The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis. J Clin Pharm Ther. 2017;42:18–26.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Altman A, Pui C-H, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26:2767–2778.
   PubMed Web of Science ®Google Scholar
• Mehta RL, Awdishu L, Davenport A, et al. Phenotype standardization for drug-induced kidney disease. Kidney Int. 2015;88:226–234.
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019–5032.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index: a risk model for cns relapse in patients with diffuse large b-cell lymphoma treated with R-CHOP. Jco. 2016;34:3150–3156.
   PubMed Web of Science ®Google Scholar
• Lacasce A, Howard O, Li S, et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004;45:761–767.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369:1915–1925.
   PubMed Web of Science ®Google Scholar
• Mcphail ED, Maurer MJ, Macon WR, et al. Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements. Haematologica 2018;103:1899–1907.
   PubMed Web of Science ®Google Scholar
• Coca SG, Peixoto AJ, Garg AX, et al. The prognostic importance of a small acute decrement in kidney function in hospitalized patients: a systematic review and meta-analysis. Am J Kidney Dis. 2007;50:712–720.
   PubMed Web of Science ®Google Scholar
• Frazee EN, Leedahl DD, Kashani KB. Key controversies in colloid and crystalloid fluid utilization. Hosp Pharm. 2015;50:446–453.
   PubMedGoogle Scholar
• Candrilli S, Bell T, Irish W, et al. A comparison of inpatient length of stay and costs among patients with hematologic malignancies (excluding Hodgkin disease) associated with and without acute renal failure. Clin Lymphoma Myeloma. 2008;8:44–51.
   PubMedGoogle Scholar
• Hummel M, Reiter S, Adam K, et al. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol. 2008;80:331–336.
   PubMed Web of Science ®Google Scholar
• Usami E, Kimura M, Iwai M, et al. Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase. Mol Clin Oncol. 2017;6:955–959.
   PubMed Web of Science ®Google Scholar
• Mato AR, Riccio BE, Qin L, et al. A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma. 2006;47:877–883.
   PubMed Web of Science ®Google Scholar
• Welch HK, Kellum JA, Kane-Gill SL. Drug-associated acute kidney injury identified in the united states food and drug administration adverse event reporting system database. Pharmacotherapy. 2018;38:785–793. Aug [cited 2018 Nov 17] Available from: http://www.ncbi.nlm.nih.gov/pubmed/29883524
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49:325–327. Aug 1 [cited 2018 Nov 17] Available from: https://academic.oup.com/cid/article-lookup/doi/10.1086/600877
   PubMed Web of Science ®Google Scholar
• Robertson AD, Li C, Hammond DA, et al. Incidence of acute kidney injury among patients receiving the combination of vancomycin with piperacillin-tazobactam or meropenem. Pharmacother J Hum Pharmacol Drug Ther [Internet] 2018; Oct 3 [cited 2018 Nov 17]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/30175410
   Google Scholar
• Pui C-H, Mahmoud HH, Wiley JM, et al. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. Clin Oncol. 2001;19:1–12.
   Web of Science ®Google Scholar
• McBride A, Lathon SC, Boehmer L, et al. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome. Pharmacotherapy. 2013;33:295–303.
   PubMed Web of Science ®Google Scholar
• Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001;97:2998–3003.
   PubMed Web of Science ®Google Scholar
• Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone–results of a multicenter phase III study. Jco. 2010;28:4207–4213.
   PubMed Web of Science ®Google Scholar
• Cairo MS, Thompson S, Tangirala K, et al. A clinical and economic comparison of rasburicase and allopurinol in the treatment of patients with clinical or laboratory tumor lysis syndrome. Clin Lymphoma Myeloma Leuk. 2017;17:173–178.
   PubMed Web of Science ®Google Scholar